Shared the AHIP 2026 stage last week with
@aboehler and
@peter_orszag to debate healthcare affordability + policy. Some of our takes:
🔥 Healthcare affordability has not improved in the last few years, and has even gotten worse in several areas.
🔥 We've also all aged ~20 years in the last 3 due to the rate of policy and regulatory change in gov't health insurance markets - e.g. MA v28 + new rate notice, Medicaid work requirements under HR-1, ACA subsidy cliff, etc... the health plans are fatigued (and still have a ton of work to do to actually implement and execute against these changes).
🔥 And at the same time - innovation is accelerating! From GLP-1s, cell and gene therapies, to AI-enabled care models. While these technological advancements promise profound health impact, broad affordability for them has not yet been solved. Good policy needs to address market failures related to risk pools, time horizons for underwriting said risk, and pragmatic payment models with teeth behind them.
🔥 Consumer-directed cash-pay is still a rounding error of total spend today... but we should keep an eye on the trend: consumers are waking up to the fact that they're burning $1,000s inside their own deductible for opaque, overpriced services + a miserable UX. Cash-pay-optimized suppliers are rushing into that void - and people are voting with those deductible dollars. e.g.
@function,
@CounselHealth,
@truemed, et al are winning a rapidly growing following based on superior value and experience that the insurance-optimized system is not incentivized to deliver. Will these kinds of players eventually constitute the future version of health insurance?
🔥 In 2025, providers were out front on AI while health plans were playing defense... but in 2026, the plans are clearly leaning in, across both internal ops and external member- and provider- facing experience.
In 5 years, if we're saying healthcare affordability got better, it'll be because we finally embraced AI to bring down the cost structure of care on BOTH ends of the acuity curve. The low end is obvious. The high end - the sickest, most comorbid patients - is where we were most hesitant to say exactly what the near-term impact could be.... but therein is the grand challenge for builders: bend the cost curve in areas where the system looks the most AI-proof.